12 February 2016 in PLOS ONE
Pancreatic cancer is an aggressive disease with dismal prognosis. It is of paramount importance to understand the underlying etiological mechanisms and identify novel, consistent, and easy-to-apply prognostic factors for precision therapy. TUSC3 (tumor suppressor candidate 3) was identified as a potential tumor suppressor gene and previous study showed TUSC3 is decreased in pancreatic cancer at mRNA level, but its putative tumor suppressor function remains to be verified. In this study, TUSC3 expression was found to be suppressed both at mRNA and protein levels in cell line models as well as in clinical samples; decreased TUSC3 expression was associated with higher pathological TNM staging and poorer outcome. In three pairs of cell lines with different NF-κB activity, TUSC3 expression was found to be reversely correlated with NF-κB activity. TUSC3-silenced pancreatic cancer cell line exhibited enhanced potential of proliferation, migration and invasion. In an orthotopic implanted mice model, TUSC3 silenced cells exhibited more aggressive phenotype with more liver metastasis. In conclusion, the current study shows that decreased immunological TUSC3 staining is a factor prognostic of poor survival in pancreatic cancer patients and decreased TUSC3 promotes pancreatic cancer cell proliferation, invasion and metastasis. The reverse correlation between NF-κB activity and TUSC3 expression may suggest a novel regulation pattern for this molecule.
1 September 2018 in Medicine
Langerhans cell histiocytosis (LCH) is a relatively rare disorder characterized by the proliferation of abnormal Langerhans cells. Splenic involvement usually presents in children with multisystem LCH, and isolated LCH of the spleen is a very rare disease. Herein, we report a case of isolated splenic LCH in an adult man. We report a case of isolated splenic LCH that first manifested with recurrent left upper abdominal pain. Unenhanced CT revealed multiple nodular lesions located at the spleen. Magnetic resonance imaging speculated that these lesions were lymphomas. On the basis of histopathological and immunohistochemical findings, the diagnosis of isolated splenic LCH was confirmed. The patient underwent splenectomy. Histopathologic examination revealed the proliferation of Langerhans cell. Immunohistochemical staining revealed that cells of the tumor were positive for S-100, CD1a, CD45RO, and Vimentin. The patient is alive without recurrence 9 years after operation. Isolated LCH of the spleen may have a favorable prognosis and splenectomy is an effective therapeutic method.
6 February 2023 in Oncology Reports
Following the publication of this article, a concerned reader drew to the Editor's attention that various of the data panels showing the results from Transwell cell migration and invasion assay experiments in Figs. 2D and 4D contained groupings of cells that were markedly similar, even though the cells appeared in separate panels that were intended to show the results from different experiments. In addition, the cell images shown in Fig. 2B were strikingly similar to data that had appeared in different form in another article published by different authors at a different research institution. After having conducted an internal investigation of this matter, the Editor of Oncology Reports has judged that the groupings of cells, appearing as they did among various different panels in Figs. 2 and 4, were too extensive that their apperance could have been attributed to pure coincidence. Also in view of the fact that some of the data were derived from a previously published source, the Editor has decided that this article should be retracted from the publication. After having been in contact with the authors of this study, they agreed with the Editor's decision to retract this article. The Editor sincerely apologizes to the readership for any incovenience caused, and we thank the reader for bringing this matter to our attention. [Oncology Reports 38: 301‑308, 2017; DOI: 10.3892/or.2017.5705]